Combination Therapy in Renal Cell Carcinoma: Expert Guidance to Individualize Treatment and Improve Outcomes

Download slidesets from our live webinar covering the latest clinical data on immune checkpoint inhibitor&ndash based combination therapies for the treatment of advanced or metastatic RCC.

Share

Program Content

Activities

First-line Treatment for RCC
Planning Optimal First-line Treatment for Patients With Advanced RCC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2021

Expires: June 15, 2022

Salvage Therapy for RCC
Evolving Salvage Systemic Therapy in Metastatic Renal Cell Carcinoma in 2021
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2021

Expires: June 15, 2022

Managing irAEs for RCC
Optimal Management of Immune-Related Adverse Events for Patients With Advanced RCC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2021

Expires: June 15, 2022

<i>EP</i>: Combination Therapy in RCC
ExpressPoints:
Combination Therapy in Renal Cell Carcinoma: Expert Guidance to Individualize Treatment and Improve Outcomes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2021

Expires: June 15, 2022

Faculty

cover img faculity

Neeraj Agarwal, MD

Professor of Medicine
Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

cover img faculity

Eric Jonasch, MD

Assistant Professor, Genitourinary Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

cover img faculity

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Eisai

Exelixis, Inc.

Merck Sharp & Dohme Corp.